Displaying drugs 14176 - 14200 of 15520 in total
Sofinicline
Sofinicline has been used in trials studying the treatment of ADHD, Neuralgia, Diabetic, Diabetic Neuropathies, Diabetic Polyneuropathy, and Diabetic Neuropathic Pain, among others.
Investigational
Matched Description: … studying the treatment of ADHD, Neuralgia, Diabetic, Diabetic Neuropathies, Diabetic Polyneuropathy, and …
WP-1066
WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central Nervous System Neoplasms.
Investigational
Matched Description: … WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central …
AZD-8055
AZD8055 has been used in trials studying the treatment of Cancer, Lymphomas, Solid Tumors, MALIGNANT GLIOMA, and brainstem glioma, among others.
Investigational
Matched Description: … has been used in trials studying the treatment of Cancer, Lymphomas, Solid Tumors, MALIGNANT GLIOMA, and …
Phthalocyanine
Phthalocyanine is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
Investigational
AZD-8418
Azd8418 is under investigation in clinical trial NCT01027234 (This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses).
Investigational
Matched Description: … Azd8418 is under investigation in clinical trial NCT01027234 (This Study Will Assess the Safety and Tolerability …
Talastine
Experimental
Imipramine oxide
Experimental
AS1409
AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours. It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and...
Investigational
Matched Description: … It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma …
KD3010
KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.
Investigational
LAX-101
LAX-101 treats hungtington’s disease, not just the symptoms but the disease itself. The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical. The molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements.
Investigational
VTP-201227
VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications. It is being developed by Vitae Pharmaceuticals.
Investigational
Matched Description: … VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment …
ALKS 29
ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.
Investigational
PF-03187207
PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. The development of abnormally high IOP, due to blockage...
Investigational
Matched Description: … Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF- …
Norclozapine
ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.
Investigational
Matched Description: … ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA …
Manitimus
FK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in kidney transplant patients, potentially offering a breakthrough in immunosuppressive therapy.
Investigational
Matched Description: … FK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in …
2,6-diaminoquinazolin-4-ol
Experimental
9-Deazaguanine
Experimental
5-[2-(TRIFLUOROMETHYL)PHENYL]-2-FUROIC ACID
Experimental
(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
Experimental
Clorsulon
Vet approved
Aminopentamide
Experimental
Vet approved
2,2':6',2''-Terpyridine Platinum(Ii)
2,2':6',2''-terpyridine Platinum(Ii) is a solid. Known drug targets of 2,2':6',2''-Terpyridine Platinum(Ii) include truncated transposase and autolysin.
Experimental
Matched Description: … Known drug targets of 2,2':6',2''-Terpyridine Platinum(Ii) include truncated transposase and autolysin …
Displaying drugs 14176 - 14200 of 15520 in total